ライフサイエンスコーパス: lymphoproliferative

1 was inflammatory, followed by structural and lymphoproliferative.

2 H1N1-specific T-cell responses in lymphoproliferative and IFN-gamma assays were detectable

3 e lacking NFkappaB1 (Nfkappab1(-/-)) develop lymphoproliferative and multiorgan autoimmune disease at

4 e of MGUS in blood relatives of persons with lymphoproliferative and plasma cell proliferative disord

5 l-mediated immune responses as assessed by a lymphoproliferative assay.

6 tectable in survivors' peripheral blood, and lymphoproliferative assays were negative in the three fa

7 A complex resulted in a severe, multi-organ, lymphoproliferative autoimmune disorder.

8 etained T-cell epitopes, as evident from its lymphoproliferative capacity but down-regulated pro-alle

9 d biopsy should be conducted to identify the lymphoproliferative clone.

10 I, 1.03-3.10; P = 0.038) and post-transplant lymphoproliferative disease (adjusted HR, 2.72; 95% CI,

11 Dianzani autoimmune lymphoproliferative disease (DALD) has a similar phenoty

12 te activity can lead to life-threatening EBV lymphoproliferative disease (EBV-PTLD).

13 rare Epstein-Barr virus (EBV)-driven B-cell lymphoproliferative disease (LPD).

14 Optimal upfront therapy for posttransplant lymphoproliferative disease (PTLD) arising after solid o

15 city (p = 0.014) and previous posttransplant lymphoproliferative disease (PTLD) diagnosis (p = 0.006)

16 Posttransplantation lymphoproliferative disease (PTLD) is an often Epstein-B

17 Optimal therapy for posttransplant lymphoproliferative disease (PTLD) remains problematic.

18 Optimal management of posttransplant lymphoproliferative disease (PTLD) remains to be defined

19 irus (EBV) is associated with posttransplant lymphoproliferative disease (PTLD), and EBV load measure

20 ding Burkitt's lymphoma (BL), posttransplant lymphoproliferative disease (PTLD), nasopharyngeal carci

21 d III latency tumors, such as posttransplant lymphoproliferative disease (PTLD), on EBV I latency tum

22 central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD).

23 ant recipients are at risk of posttransplant lymphoproliferative disease (PTLD).

24 infections and trigger post-transplantation lymphoproliferative disease (PTLD).

25 One of the manifestations of X-linked lymphoproliferative disease (XLP) is progressive agammag

26 s with the primary immunodeficiency X-linked lymphoproliferative disease (XLP), which is caused by mu

27 T cells from patients with X-linked lymphoproliferative disease (XLP), who lack functional S

28 ls from SAP-deficient patients with X-linked lymphoproliferative disease (XLP).

29 X-linked lymphoproliferative disease (XLP1) arises from mutations

30 ergistic signalling is defective in X-linked lymphoproliferative disease (XLP1) NK cells entailing 2B

31 X-linked lymphoproliferative disease 1 (XLP1), due to mutations i

32 e causal gene responsible for XLP2 (X-linked lymphoproliferative Disease 2).

33 y, and EBV-related morbidity (posttransplant lymphoproliferative disease [PTLD] or symptomatic EBV in

34 is a complex retrovirus associated with the lymphoproliferative disease adult T-cell leukemia/lympho

35 ontaneously mounting a severe autoaggressive lymphoproliferative disease and can modulate immune resp

36 ase but not in EBV-associated posttransplant lymphoproliferative disease and Hodgkin disease.

37 n-Barr virus (EBV)-associated posttransplant lymphoproliferative disease and melanoma.

38 These mice develop a lymphoproliferative disease and occasional transformatio

39 ometimes fatal syndromes, including X-linked lymphoproliferative disease and severe cases of common v

40 ponse rates in patients with post-transplant lymphoproliferative disease as well as EBV-positive lymp

41 g Pten in Treg cells developed an autoimmune-lymphoproliferative disease characterized by excessive T

42 ty genes (RAB27A, LYST, and AP3B1), X-linked lymphoproliferative disease genes (SH2D1A and XIAP), and

43 n cancer, Kaposi sarcoma, and posttransplant lymphoproliferative disease have standardized incidence

44 Marek's disease virus (MDV) causes a deadly lymphoproliferative disease in chickens and modulates me

45 human malignancies including posttransplant lymphoproliferative disease in immunosuppressed patients

46 Individuals with X-linked lymphoproliferative disease lack invariant natural kille

47 This acute and lethal lymphoproliferative disease occurs after a prolonged asy

48 Marek's disease (MD) is a lymphoproliferative disease of chickens caused by the on

49 anular lymphocyte (LGL) leukemia is a clonal lymphoproliferative disease of mature T and natural kill

50 ces malignant catarrhal fever (MCF), a fatal lymphoproliferative disease of ruminants, including catt

51 duced in T cells from patients with X-linked lymphoproliferative disease or normal T cells transfecte

52 Furthermore, in X-linked lymphoproliferative disease patients, SAP deficiency red

53 We analyzed the virological and lymphoproliferative disease response (LDR) of 46 patient

54 ribed patients with immune dysregulation and lymphoproliferative disease resulting from 2 different g

55 entiviruses cause an incurable, progressive, lymphoproliferative disease that affects millions of ani

56 granular lymphocytic leukaemia (T-LGL) is a lymphoproliferative disease that presents with immune-me

57 unopathology of IM in boys with the X-linked lymphoproliferative disease trait, and as a chronic acti

58 ity using B6(mir146a-/-) mice and a model of lymphoproliferative disease using the well-characterized

59 h adult T-cell leukemia (ATL), an aggressive lymphoproliferative disease with a dismal prognosis.

60 ed homeostatic expansion, which manifests as lymphoproliferative disease with autoantibody production

61 nce of approximately 80% (49% splenic B-cell lymphoproliferative disease, 28% lymphoma).

62 y immunogenic tumors such as post-transplant lymphoproliferative disease, although resistance occurre

63 eration, vascular thrombosis, posttransplant lymphoproliferative disease, and estimated glomerular fi

64 stromal lymphopoietin levels, milder B-cell lymphoproliferative disease, and improved survival in Ms

65 cleosis, hemophagocytic lymphohistiocytosis, lymphoproliferative disease, and/or EBV+ B-cell lymphoma

66 ases of GI involvement by an indolent T-cell lymphoproliferative disease, including 6 men and 4 women

67 O mice developed lupus-like autoimmunity and lymphoproliferative disease, indicating that ubiquitin l

68 ne function; however, treated mice developed lymphoproliferative disease, likely due to viral-promote

69 cleosis, hemophagocytic lymphohistiocytosis, lymphoproliferative disease, organomegaly, and/or malign

70 aired in T cells from patients with X-linked lymphoproliferative disease, which lack SLAM-associated

71 The boy developed posttransplant lymphoproliferative disease, which resolved after treatm

72 TNF-family receptor result in autoimmune and lymphoproliferative disease.

73 reated before HSCT because of EBV-associated lymphoproliferative disease.

74 entially fatal EBV-associated posttransplant lymphoproliferative disease.

75 many are at increased risk of virus-driven B-lymphoproliferative disease.

76 e targeted in T cell therapy of EBV-driven B-lymphoproliferative disease.

77 in whom it can cause life-threatening B cell lymphoproliferative disease.

78 ne EVR/rTAC patient developed posttransplant lymphoproliferative disease.

79 onucleosis or its fatal equivalent, X-linked lymphoproliferative disease; (ii) EBV infection in a ran

80 drome/myeloproliferative neoplasm (19%), and lymphoproliferative diseases (30%).

81 Posttransplantation lymphoproliferative diseases (PTLD) are mainly Epstein-B

82 (KSHV) is the causative agent of two B-cell lymphoproliferative diseases and Kaposi's sarcoma, an en

83 lls are frequently observed in several other lymphoproliferative diseases as well.

84 Lymphadenopathy in autoimmune and other lymphoproliferative diseases is in part characterized by

85 V in the pathogenesis of EBV-positive T-cell lymphoproliferative diseases largely unresolved.

86 B-cell-tropic virus associated with various lymphoproliferative diseases of both B-cell and non-B-ce

87 ped hematologic malignancies (posttransplant lymphoproliferative diseases, 18; Hodgkin disease, 2; an

88 erative syndromes, hemophagocytic disorders, lymphoproliferative diseases, and novel differential dia

89 ciated with the development of lymphomas and lymphoproliferative diseases, as well as several other t

90 ced-stage PSC was 18.7%, with posttransplant lymphoproliferative diseases, colorectal cancer, and ren

91 nstrated to promote Treg cell suppression of lymphoproliferative diseases, has an unexpected function

92 esviral infection is closely associated with lymphoproliferative diseases, including B cell lymphomas

93 etent people, EBV causes several cancers and lymphoproliferative diseases.

94 he role of EBV in the pathogenesis of T-cell lymphoproliferative diseases.

95 can potentially be targeted in autoimmune or lymphoproliferative diseases.

96 sally linked to Kaposi's sarcoma and several lymphoproliferative diseases.

97 in clinical development for treating B-cell lymphoproliferative diseases.

98 lticentric Castleman disease (MCD) and other lymphoproliferative diseases.

99 r the potential development of MCD and other lymphoproliferative diseases.

100 ses are associated with numerous cancers and lymphoproliferative diseases.

101 ndocrine/metabolic diseases, and hematologic/lymphoproliferative diseases.

102 ses infectious mononucleosis and can lead to lymphoproliferative diseases.

103 itt lymphoma and immunocompromise-associated lymphoproliferative diseases/lymphomas as well as epithe

104 velopment of three major human neoplastic or lymphoproliferative diseases: Kaposi's sarcoma (KS), pri

105 tients with classic hydroa vacciniforme-like lymphoproliferative disorder (HVLPD) typically have high

106 y et al describe cases of an indolent T-cell lymphoproliferative disorder (LPD) of the gastrointestin

107 eveloping high EBV viral load and associated lymphoproliferative disorder (LPD).

108 ival with lower incidence of post-transplant lymphoproliferative disorder (P = 0.09) and graft versus

109 tein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after a rituximab-ba

110 tandard in the management of post-transplant lymphoproliferative disorder (PTLD) and identified respo

111 Patients at greatest risk of posttransplant lymphoproliferative disorder (PTLD) are those who acquir

112 new safety signals and no new posttransplant lymphoproliferative disorder (PTLD) cases after month 18

113 Posttransplant lymphoproliferative disorder (PTLD) continues to be a de

114 guished untreated, EBV(+)posttransplantation lymphoproliferative disorder (PTLD) from EBV(+)PTLD in r

115 /CT for the detection of posttransplantation lymphoproliferative disorder (PTLD) in a pediatric popul

116 the relationship between posttransplantation lymphoproliferative disorder (PTLD) incidence and presen

117 Posttransplant lymphoproliferative disorder (PTLD) is a potentially fat

118 Posttransplant lymphoproliferative disorder (PTLD) is a serious complic

119 Posttransplantation lymphoproliferative disorder (PTLD) is a well-recognized

120 Posttransplant lymphoproliferative disorder (PTLD) is an infrequent but

121 Post-transplantation lymphoproliferative disorder (PTLD) is associated with s

122 Higher incidence of post-transplant lymphoproliferative disorder (PTLD) is reported in the p

123 Higher incidence of posttransplant lymphoproliferative disorder (PTLD) is reported in the p

124 pressive regimens (ISRs) with posttransplant lymphoproliferative disorder (PTLD) may be related with

125 n-Barr virus (EBV)-associated posttransplant lymphoproliferative disorder (PTLD) remains a major caus

126 scribe a form of plasmacytic post-transplant lymphoproliferative disorder (PTLD) that occurs in pedia

127 Posttransplantation lymphoproliferative disorder (PTLD), a complication of l

128 B-cell lymphoma (DLBCL), and posttransplant lymphoproliferative disorder (PTLD).

129 h infectious mononucleosis to posttransplant lymphoproliferative disorder (PTLD).

130 stent with a polymorphic posttransplantation lymphoproliferative disorder (PTLD).

131 skin cancer, solid tumor, and posttransplant lymphoproliferative disorder (PTLD).

132 ith the highest incidence was posttransplant lymphoproliferative disorder (PTLD, 1.58%), followed by

133 al Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial established

134 Interestingly, however, a massive lymphoproliferative disorder and cellular transformation

135 t presentations of primary cutaneous CD30(+) lymphoproliferative disorder and present recommendations

136 r, the mechanisms by which HCV causes B-cell lymphoproliferative disorder are still unclear.

137 Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated prod

138 macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined c

139 macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined c

140 cation of typical features of CAD-associated lymphoproliferative disorder in the bone marrow was grea

141 Postransplant lymphoproliferative disorder is an important concern, oc

142 Indolent T-cell lymphoproliferative disorder is usually a disease of adu

143 presents a potential treatment for the CD30+ lymphoproliferative disorder lymphomatoid papulosis (LyP

144 Anemia, neutropenia and posttransplant lymphoproliferative disorder occurred more frequently in

145 HVLL is an EBV-associated lymphoproliferative disorder of alphabeta-, gammadelta-,

146 an Epstein-Barr virus (EBV)-positive T-cell lymphoproliferative disorder of childhood that occurs ma

147 After the diagnosis of indolent T-cell lymphoproliferative disorder of the gastrointestinal tra

148 Indolent T-cell lymphoproliferative disorder of the gastrointestinal tra

149 Posttransplant lymphoproliferative disorder remains an important concer

150 t frequent type of leukaemia in adults, is a lymphoproliferative disorder that is characterized by th

151 rrier function, resulting in a more severe B-lymphoproliferative disorder that persisted into adultho

152 ttransplant malignancies, and posttransplant lymphoproliferative disorder were 3.2 (1.6-5.7), 3.2 (1.

153 hey had multiple myeloma or any other B cell lymphoproliferative disorder with end-organ damage.

154 nucleotide exchange factor Rasgrp1 develop a lymphoproliferative disorder with features of human syst

155 primary cutaneous CD4(+) small/medium T-cell lymphoproliferative disorder" because of its indolent cl

156 oup (one CMV; one EBV-related posttransplant lymphoproliferative disorder).

157 expression in cases of human posttransplant lymphoproliferative disorder, a malignant condition asso

158 lications post-ITx, including posttransplant lymphoproliferative disorder, graft-versus-host disease,

159 lticentric Castleman disease (KSHV-MCD) is a lymphoproliferative disorder, most commonly seen in HIV-

160 In the case of posttransplant lymphoproliferative disorder, the EBV DNA from the donor

161 neoplasms are a rare form of posttransplant lymphoproliferative disorder, which could be complicated

162 s, and 99.1% of patients were posttransplant lymphoproliferative disorder-free through 5 years.

163 5 x 10(9)/L B-cells and no other signs of a lymphoproliferative disorder.

164 al B-cell, and 1 CR of 3 with posttransplant lymphoproliferative disorder.

165 skin, solid malignancies, and posttransplant lymphoproliferative disorder.

166 LYG) is a rare Epstein-Barr virus-associated lymphoproliferative disorder.

167 There were no cases of lymphoproliferative disorder.

168 ow incidence of EBV reactivation without EBV-lymphoproliferative disorder.

169 xperience higher incidence of posttransplant lymphoproliferative disorder.

170 stleman disease (MCD) is a polyclonal B-cell lymphoproliferative disorder.

171 entric Castleman disease (MCD) as a distinct lymphoproliferative disorder.

172 at a median of 96 days with no incidence of lymphoproliferative disorder.

173 ere were no retransplants or post-transplant lymphoproliferative disorder.

174 risks, such as infectious mononucleosis and lymphoproliferative disorder.

175 ble, display fully penetrant female-specific lymphoproliferative disorder.

176 g a possible explanation for female-specific lymphoproliferative disorder.

177 , a life-threatening, virally induced B-cell lymphoproliferative disorder.

178 ia is a major risk factor for posttransplant lymphoproliferative disorder; however, immune correlates

179 lymphoma (SMZL), and 52 with B-cell chronic lymphoproliferative disorders (B-CLPD).

180 t an exhaustive search for pathogenic DNA in lymphoproliferative disorders (LPD) of the ocular adnexa

181 thrombocytopenia (ITP) secondary to chronic lymphoproliferative disorders (LPDs) is poorly responsiv

182 ence of EBV-infected cells results in severe lymphoproliferative disorders (LPDs).

183 e syndromes of EBV-associated posttransplant lymphoproliferative disorders (PTLD) and Kaposi's sarcom

184 Posttransplant lymphoproliferative disorders (PTLD) are a common malign

185 iated with increased risk for posttransplant lymphoproliferative disorders (PTLD) in liver transplant

186 Posttransplantation lymphoproliferative disorders (PTLD) present a major cau

187 skin cancers [NMSCs]), post-transplantation lymphoproliferative disorders (PTLD), and first and subs

188 gan transplantation (SOT) and posttransplant lymphoproliferative disorders (PTLD).

189 Posttransplant lymphoproliferative disorders (PTLDs) are associated wit

190 EBV(-) posttransplantation lymphoproliferative disorders (PTLDs) are rare compared

191 ut knowledge of their role in posttransplant lymphoproliferative disorders (PTLDs) is limited.

192 BV infection (CAEBV) characterized by T cell lymphoproliferative disorders (T-LPD) of unclear etiolog

193 mia (WM) cases, and the clustering of B-cell lymphoproliferative disorders among first-degree relativ

194 We screened 418 patients with B-cell lymphoproliferative disorders and described the presence

195 tive agent of most immune deficiency-related lymphoproliferative disorders and is associated with var

196 rstanding the viral associations in specific lymphoproliferative disorders and the molecular mechanis

197 The primary cutaneous CD30(+) lymphoproliferative disorders are a family of extranodal

198 T-cell lymphoproliferative disorders are a heterogeneous group

199 t-acting antivirals (DAAs) in HCV-associated lymphoproliferative disorders are scanty.

200 noglobulin gene rearrangements in context of lymphoproliferative disorders demonstrated excellent cle

201 sease describes a group of poorly understood lymphoproliferative disorders driven by proinflammatory

202 coexpression distinguished cutaneous CD30(+) lymphoproliferative disorders from MF large-cell transfo

203 Bacteria can induce human lymphomas, whereas lymphoproliferative disorders have been described in pat

204 ogren's syndrome in 22.5% of patients and to lymphoproliferative disorders in 28.7% of patients, and

205 n was also found in EBV/KSHV dually infected lymphoproliferative disorders in humans.

206 ation was associated with the development of lymphoproliferative disorders in mice.

207 ents for CWID and RICD leads to autoimmunune lymphoproliferative disorders in mouse and human.

208 , the prognosis of primary cutaneous CD30(+) lymphoproliferative disorders is excellent; however, rel

209 h it establishes latency, and can also cause lymphoproliferative disorders of these cells manifesting

210 This case is a reminder that lymphoproliferative disorders often mimic other neurolog

211 e, proteinuria, c-peptide, viral infections, lymphoproliferative disorders or posttransplant diabetes

212 lymphomas encompass a wide spectrum of rare lymphoproliferative disorders originating in the skin, a

213 orders such as systemic lupus erythematosus; lymphoproliferative disorders such as chronic lymphocyti

214 Lymphoproliferative disorders were predominant (77%); ho

215 ting immunoglobulins that occur secondary to lymphoproliferative disorders, chronic viral infections,

216 response to immunotherapy, autoimmunity, and lymphoproliferative disorders, contributing overall to p

217 f the diffuse cystic lung diseases caused by lymphoproliferative disorders, genetic mutations, or abe

218 Assay positivity was associated with lymphoproliferative disorders, hematopoietic stem cell t

219 the development of EBV-associated lymphomas, lymphoproliferative disorders, hemophagocytic lymphohist

220 enic human virus, is associated with several lymphoproliferative disorders, including Burkitt lymphom

221 ought to increase the risk of malignancy and lymphoproliferative disorders, including hemophagocytic

222 which are associated with the development of lymphoproliferative disorders, including lymphomas, reac

223 EBV-infected B cells causes life-threatening lymphoproliferative disorders, including mostly germinal

224 miR-155 acts as an oncogenic miR in B-cell lymphoproliferative disorders, including Waldenstrom mac

225 tasizing neoplasms, polyclonal or monoclonal lymphoproliferative disorders, infections, interstitial

226 s (KSHV) is causatively linked to two B cell lymphoproliferative disorders, multicentric Castleman's

227 Among indolent B cell lymphoproliferative disorders, NOTCH2 mutations are rest

228 gent for Kaposi's sarcoma (KS) and two other lymphoproliferative disorders, primary effusion lymphoma

229 progressive kidney failure in the setting of lymphoproliferative disorders, such as multiple myeloma,

230 EBV is also associated with a variety of lymphoproliferative disorders, typically of B cell origi

231 Hodgkin and Hodgkin lymphomas, as well as in lymphoproliferative disorders, which occur more commonly

232 virus that causes Kaposi's sarcoma and other lymphoproliferative disorders.

233 mechanisms underlying HCV-associated B-cell lymphoproliferative disorders.

234 twork of target mRNAs associated with B-cell lymphoproliferative disorders.

235 somal locus 6q14.1, a mutational hot spot in lymphoproliferative disorders.

236 wel disease (IBD), rheumatoid arthritis, and lymphoproliferative disorders.

237 have also been found in patients with other lymphoproliferative disorders.

238 by its association with a variety of T-cell lymphoproliferative disorders.

239 targeted therapy for CLL and related B-cell lymphoproliferative disorders.

240 omplications, enteropathy, autoimmunity, and lymphoproliferative disorders.

241 is associated with an increased incidence of lymphoproliferative disorders.

242 enia, chronic EBV infection, and EBV-related lymphoproliferative disorders.

243 nctional polarization was examined in T-cell lymphoproliferative disorders.

244 ribute to the development of KSHV-associated lymphoproliferative disorders.

245 virus is etiologically linked to two B cell lymphoproliferative disorders.

246 munodeficiency with Epstein-Barr virus (EBV)-lymphoproliferative disorders.

247 al differences in the pathogenesis of B-cell lymphoproliferative disorders.

248 ted with neurological, gastrointestinal, and lymphoproliferative disorders.

249 increases in cardiovascular event risk, and lymphoproliferative disorders.

250 inhibition (HI), microneutralization, ELISA, lymphoproliferative, ELISpot IFN-gamma, and cytokine and

251 SLAM)-associated protein (SAP), the X-linked lymphoproliferative gene product.

252 patients (71%) had concurrent autoimmune or lymphoproliferative illnesses related to immune dysregul

253 ed multicentric Castleman disease (MCD) is a lymphoproliferative inflammatory disorder commonly assoc

254 mice; 3 of 6 of these animals also developed lymphoproliferative lesions after 12 months of infection

255 oproliferative syndrome (ALPS) in humans and lymphoproliferative (LPR) disease in mice result from ab

256 an antiproliferative effect of SCF(FBXL2) in lymphoproliferative malignancies.

257 CD) is associated with an increased risk for lymphoproliferative malignancy (LPM).

258 leosis and chronic infections that result in lymphoproliferative malignant diseases.

259 ory (n = 51; 53%), structural (n = 20; 21%), lymphoproliferative (n = 19; 20%), and uncommon (n = 7;

260 Twenty-two patients with heavily pretreated lymphoproliferative or myeloid malignancies were treated

261 manifestations and, at a lesser extent, the lymphoproliferative phenotype and prolongs survival in M

262 actor responsible for ERK activation and the lymphoproliferative phenotype in these mice.

263 erogeneous group of primary cutaneous T-cell lymphoproliferative processes, mainly composed of mycosi

264 T cell lymphoproliferative responses and levels of IFN-gamma we

265 nonuclear cell phytohemagglutinin-stimulated lymphoproliferative responses decreased significantly wi

266 Lymphoproliferative responses in infected human PBMCs we

267 All children (N = 12) with autoimmune lymphoproliferative syndrome (ALPS) achieved a durable c

268 Autoimmune lymphoproliferative syndrome (ALPS) caused by impaired F

269 Autoimmune lymphoproliferative syndrome (ALPS) in humans and lympho

270 Autoimmune lymphoproliferative syndrome (ALPS) is a human disorder

271 Autoimmune lymphoproliferative syndrome (ALPS) is a human disorder

272 Autoimmune lymphoproliferative syndrome (ALPS) is a rare immunodefi

273 Autoimmune lymphoproliferative syndrome (ALPS) is caused by inactiv

274 Autoimmune lymphoproliferative syndrome (ALPS) is characterized by

275 ocument a 20-year experience with autoimmune lymphoproliferative syndrome (ALPS) patients and healthy

276 Autoimmune lymphoproliferative syndrome (ALPS) presents in childhoo

277 In autoimmune/lymphoproliferative syndrome (ALPS), defective Fas death

278 human apoptosis disorders is the autoimmune lymphoproliferative syndrome (ALPS), which is caused by

279 arkable efficacy in children with autoimmune lymphoproliferative syndrome (ALPS).

280 ve T cells (DNT) is a hallmark of autoimmune lymphoproliferative syndrome (ALPS).

281 wo distinct inflammatory disorders, X-linked lymphoproliferative syndrome 2 (XLP-2) and very-early-on

282 Fas death receptor or its ligand result in a lymphoproliferative syndrome and exacerbate clinical dis

283 uencing in a patient with NDM and autoimmune lymphoproliferative syndrome and his unrelated, unaffect

284 activated, resulting in the development of a lymphoproliferative syndrome in these mice.

285 X-linked lymphoproliferative syndrome type-2 (XLP-2) is associate

286 gnificant immunodeficiency and an autoimmune lymphoproliferative syndrome with marked predisposition

287 e immunodeficiency in addition to autoimmune lymphoproliferative syndrome(4-6).

288 ivation in iMCD was comparable to autoimmune lymphoproliferative syndrome, a disease driven by mTOR h

289 us mutation in ITK presented with autoimmune lymphoproliferative syndrome, and had impaired TCR-drive

290 CD4(-)CD8(-) T cells, therefore exacerbating lymphoproliferative syndrome, autoimmunity, and organ in

291 Lymphoproliferative syndrome, production of anti-dsDNA A

292 (1,2) or its ligand FASL(3) cause autoimmune lymphoproliferative syndrome, whereas mutations in caspa

293 otential treatments for lupus and autoimmune lymphoproliferative syndrome, without compromising norma

294 ain of STAT5B that presented with autoimmune lymphoproliferative syndrome-like features.

295 toimmunity and lymphomagenesis of autoimmune lymphoproliferative syndrome.

296 ical role of IL-6 in the development of this lymphoproliferative syndrome.

297 systemic lupus erythematosus and autoimmune lymphoproliferative syndrome.

298 on variable immunodeficiency, and autoimmune lymphoproliferative syndromes, hemophagocytic disorders,

299 loss of PDX models due to the development of lymphoproliferative tumors (LTs) is costly and inefficie

300 Patients with X-linked lymphoproliferative (XLP) disease due to deficiency in t